AbbVie completes acquisition of Cerevel Therapeutics to strengthen neuroscience portfolio
Acquiring Company
AbbVie Inc.
Acquired Company
Cerevel Therapeutics
North ChicagoCambridgeManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaPharmaceutical ManufacturingDescription
AbbVie has successfully completed the acquisition of Cerevel Therapeutics, enabling the expansion of AbbVie's neuroscience portfolio. With this acquisition, AbbVie aims to deliver sustainable long-term performance and develop new and better tolerated therapies for patients living with neurological and psychiatric conditions.
Quick answer
AbbVie Inc. is acquiring Cerevel Therapeutics, announced August 1, 2024. AbbVie Inc. is based in North Chicago, Illinois, United States.
- How much did AbbVie Inc. pay for Cerevel Therapeutics?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Cerevel Therapeutics based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. Cerevel Therapeutics is based in Cambridge, Maryland, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Edwards Lifesciences Completes Acquisitions of JenaValve Technology and Endotronix (July 24, 2024)
- AbbVie completes acquisition of Celsius Therapeutics, Inc. to advance therapies for inflammatory disease (June 27, 2024)
- Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio (July 8, 2024)
- Eli Lilly and Company completes $3.2 Billion Acquisition of Morphic Holding, Boosting Its IBD Pipeline, $3.2B (August 27, 2024)
- Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease (August 16, 2024)
- Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (August 9, 2024)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Cerevel Therapeutics?
Cerevel Therapeutics was acquired by AbbVie Inc., based in North Chicago. The deal was reported on August 1, 2024. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Cerevel Therapeutics?
AbbVie Inc.'s acquisition of Cerevel Therapeutics was reported on August 1, 2024. AbbVie has successfully completed the acquisition of Cerevel Therapeutics, enabling the expansion of AbbVie's neuroscience portfolio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cerevel Therapeutics do?
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. It is privately held, operating in Pharmaceutical Manufacturing, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.